Real-world experience of ocrelizumab in MS in the Turkish population: A single-center study

Basit Öğe Kaydı
dc.contributor.authorKoc, E.
dc.contributor.authorSaridas, F.
dc.contributor.authorCeylan, D.
dc.contributor.authorTuran, O.
dc.contributor.authorOzkaya, G.
dc.date.accessioned2024-09-29T16:12:24Z
dc.date.available2024-09-29T16:12:24Z
dc.date.issued2022
dc.departmentKarabük Üniversitesien_US
dc.description.abstract[No abstract available]en_US
dc.identifier.endpage792en_US
dc.identifier.issn1351-5101
dc.identifier.issn1468-1331
dc.identifier.startpage792en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14619/8726
dc.identifier.volume29en_US
dc.identifier.wosWOS:000815254003320en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofEuropean Journal of Neurologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleReal-world experience of ocrelizumab in MS in the Turkish population: A single-center studyen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu